Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Other Non Operating Income for 15 consecutive years, with $277000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 18.77% year-over-year to $277000.0, compared with a TTM value of $5.2 million through Dec 2025, up 384.19%, and an annual FY2025 reading of $5.3 million, up 400.86% over the prior year.
  • Other Non Operating Income was $277000.0 for Q4 2025 at Arrowhead Pharmaceuticals, down from $4.7 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $4.7 million in Q3 2025 and bottomed at -$3.1 million in Q3 2024.
  • Average Other Non Operating Income over 5 years is $350400.0, with a median of $323500.0 recorded in 2023.
  • Peak annual rise in Other Non Operating Income hit 2262.5% in 2024, while the deepest fall reached 534.87% in 2024.
  • Year by year, Other Non Operating Income stood at -$707000.0 in 2021, then surged by 171.71% to $507000.0 in 2022, then fell by 16.96% to $421000.0 in 2023, then dropped by 19.0% to $341000.0 in 2024, then dropped by 18.77% to $277000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for ARWR at $277000.0 in Q4 2025, $4.7 million in Q3 2025, and -$176000.0 in Q2 2025.